#Genotype Diversity of Highly Pathogenic Avian #Influenza #H5N1 Clade 2.3.4.4b in #Pennsylvania #Poultry During Disease #Outbreak from April 2022 to March 2023

 

Abstract

The 2022 highly pathogenic avian influenza (HPAI) outbreak of H5N1 clade 2.3.4.4b was one of the major avian influenza outbreaks, leading to multiple spillover events infecting domestic and wild bird flocks, as well as mammals. The sustained spread was a result of viral circulation in wild birds across migratory flyways in North America. Pennsylvania has a significant poultry population that supports both retail and live bird markets. The state also features migratory bird stopovers on the Atlantic flyway, increasing exposure to HPAI infections. This study investigates clinical presentation and sequence data from H5N1 clade 2.3.4.4b viruses during the 2022 outbreak in Pennsylvania. Eight different H5N1 clade 2.3.4.4b genotypes were detected (A1, B1.1, B1.2, B1.3, B2.2, B3.3, B3.5, and one minor genotype) during the first year. The earliest detection was genotype A1, a fully Eurasian virus, in commercial poultry in April 2022. All other genotypes identified were reassortants of A1 with North American avian influenza gene segments (denoted with “B”). Genotype B3.3 was a rare genotype prior to the initial spillover into the live bird market system, but remained predominant among backyard flocks in Pennsylvania and surrounding states until September 2023. Genotype B3.3 has not been detected in migratory waterfowl since, suggesting the genotype has waned and is no longer in circulation. This study sheds light on the genotype diversity of H5N1 during the 2022 outbreak in Pennsylvania poultry, contributing to the understanding of virus evolution and its potential impacts.

Source: 

Link: https://www.mdpi.com/1999-4915/18/5/502

____

Operational #zoonotic #containment of #MERS #coronavirus in #Saudi Arabia: An implementation-oriented #OneHealth genomic #framework

 

Abstract

Background and Aim: 

Middle East respiratory syndrome coronavirus (MERS-CoV) remains a persistent zoonotic threat more than a decade after its first detection, with Saudi Arabia continuing to be the global epicenter of human infections and the main reservoir interface through dromedary camels. Despite ongoing surveillance, advances in molecular diagnostics, and research on vaccines and therapeutics, sporadic zoonotic spillovers and healthcare-associated outbreaks still occur, showing that current prevention strategies are still not enough. This review compiles current evidence from epidemiological studies, camel reservoir research, genomic monitoring, and public health reports published between 2012 and April 2025 to identify the key gaps preventing effective containment. Special focus is given to recent genomic discoveries, including post-2022 clade B sublineages, recombination events, and spike protein changes that might affect transmission and the effectiveness of countermeasures. Available data suggest that MERS-CoV epidemiology is driven by repeated camel-to-human transmission, followed by occasional amplification in healthcare settings rather than sustained community spread. High seroprevalence and frequent detection of viral RNA in juvenile camels, seasonal gathering in markets, and extensive animal movement networks contribute to ongoing viral circulation at the animal–human interface. Genomic studies consistently show close phylogenetic relationships between camel and human isolates, confirming recurrent zoonotic transmissions. However, fragmented surveillance systems, delayed genomic data integration, inconsistent biosecurity practices, and limited field evidence for camel vaccination pose major barriers to control. Additionally, hospital outbreaks continue to occur due to delayed diagnosis, overcrowding, and incomplete adherence to infection-prevention protocols, underscoring the need for improved clinical preparedness. Based on the integrated synthesis of epidemiological, veterinary, and genomic evidence, this review proposes an implementation-focused One Health genomic framework tailored to the Saudi context. The proposed roadmap highlights real-time connection of human and camel surveillance, expands genomic sequencing capacity, targets vaccination strategies in camels and high-risk human populations, standardizes biosecurity measures in markets and abattoirs, and strengthens infection control systems in healthcare facilities. Alignment with national governance structures and Saudi Vision 2030 offers a practical pathway for coordinated multi-sectoral action. This review concludes that MERS-CoV is unlikely to be eradicated soon, but it can be effectively managed through a genomics-enabled, operational One Health approach that combines surveillance, vaccination, clinical preparedness, and policy coordination. The model outlined here provides a scalable way to reduce zoonotic spillover risk and strengthen readiness against future coronavirus and emerging zoonotic threats. 

Source: 

Link: https://veterinaryworld.org/Vol.19/March-2026/29.php

____

Avian #Influenza #Report - Reporting period: April 19 - 25 '26 (Wk 17) (HK CHP, April 28 '26): 1 new human case of #H5N1 virus in #Cambodia

 

{Excerpts}

(...)

{-- H5N1:}

- Date of report: 22/04/2026 

- Country: Cambodia

- Province / Region: Svay Rieng province

- District / City: Romduol district

- Sex: Female

- Age: 66 

- Condition at time of reporting: Hospitalised 

- Subtype of virus: H5N1 

(...)

Source: 

Link: https://www.chp.gov.hk/files/pdf/2026_avian_influenza_report_vol22_wk17.pdf

____

Serologic #Surveillance of Highly Pathogenic Avian #Influenza Virus Subtype #H5 in #Wildlife, Northeast #Germany, 2023–2025

 

Abstract

We tested wild ruminants, boar, and carnivores in northeast Germany for highly pathogenic avian influenza subtype H5 antibodies. Wild ruminants were seronegative, but 3.5% of boar and 12.5%–21.9% of carnivores were seropositive, indicating frequent spillover. Because such events might accelerate mammalian (and ultimately human) adaptation, sustained monitoring remains essential.

Source: 

Link: https://wwwnc.cdc.gov/eid/article/32/5/25-1555_article

____

Evaluation of Cross-Immunogenicity of #Ferret #Antisera Following Immunization with #H5N1 #Vaccine Strains

 

Abstract

Background: 

Highly pathogenic avian influenza H5N1 viruses of clade 2.3.4.4b have spread globally since 2021, causing extensive outbreaks in avian populations and repeated spillovers into diverse mammalian hosts, including humans. These cross-species transmission events highlight ongoing pandemic risks and underscore the need for vaccine strategies that reflect viral evolution at the human–animal interface. Despite the availability of licensed H5 vaccines and newly recommended World Health Organization (WHO) candidate vaccine viruses (CVVs), the extent to which these vaccines elicit cross-reactive antibody responses against contemporary clade 2.3.4.4b viruses, including mammalian spillover isolates of avian origin, remains incompletely characterized. 

Method: 

In this study, ferret antisera were generated using four WHO-recommended H5 CVVs, including a clade 1 strain (A/Vietnam/1194/2004) and three clade 2.3.4.4b strains (A/Astrakhan/3212/2020, A/American wigeon/South Carolina/22-000345-001/2021, and A/Ezo red fox/Hokkaido/1/2022), formulated with alum adjuvant to reflect licensed vaccine formulation used in national preparedness programs. Antibody responses and cross-reactive activity were evaluated using hemagglutination inhibition (HI) and microneutralization (MN) assays against homologous vaccine strains and a feline-origin clade 2.3.4.4b H5N1 field isolate from Korea, A/Feline/Korea/SNU-01/2023. 

Results: 

Antisera induced by clade 2.3.4.4b CVVs showed cross-reactive antibody responses against homologous and heterologous clade 2.3.4.4b viruses and demonstrated measurable HI and MN responses against the feline-origin field isolate. In contrast, antisera raised against the clade 1 Vietnam CVV exhibited limited cross-reactivity against clade 2.3.4.4b viruses. Overall, clade 2.3.4.4b CVVs generally showed higher antibody responses than the clade 1 vaccine strain across multiple panels. 

Conclusions: 

These findings provide descriptive insights into antigenic differences between clade 1 and clade 2.3.4.4b viruses and support the antigenic relevance of clade 2.3.4.4b CVVs for contemporary H5N1 strains. This study highlights the importance of ongoing antigenic evaluation to inform vaccine strain selection within a One Health framework.

Source: 

Link: https://www.mdpi.com/2076-393X/14/4/301

____

Seasonal forcing and waning #immunity drive the sub-annual periodicity of the #COVID19 #epidemic

 

Abstract

Seasonal trends in infectious diseases are shaped by climatic and social factors, with many respiratory viruses peaking in winter. However, the seasonality of COVID-19 remains in dispute, with significant waves of cases across the United States occurring in both winter and summer. Using wavelet analysis of COVID-19 cases during the pandemic period, we find that the periodicity of epidemic COVID-19 varies markedly across the U.S. and correlates with winter temperatures, indicating seasonal forcing. However, seasonal forcing alone cannot explain the pattern of multiple waves per year that has been so characteristic of COVID-19. Using a modified SIRS model that allows specification of the tempo of waning immunity, we show that specific forms of non-durable immunity can sufficiently explain the sub-annual waves characteristic of the COVID-19 epidemic.

Source: 

Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014169

____

Retrospective #Phylogenetic Analysis of #Mayaro Virus, French #Guiana, 1996–2024

 

Abstract

We conducted a retrospective phylogenetic analysis of Mayaro virus (MAYV) detected in French Guiana during 1996–2024. Analysis revealed circulation of MAYV genotype D sublineage 2 and suggested introduction from Brazil and spread to Haiti and Venezuela. Phylogenetic findings support endemic circulation and reinforce the need for MAYV surveillance in the region.

Source: 

Link: https://wwwnc.cdc.gov/eid/article/32/5/25-1435_article

____

History of Mass Transportation: The ''Crocodile of the Drinc'' Electric Locomotive in Cogne Museum

 {Click on Image to Enlarge}

Di Patafisik - Opera propria, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=175713586

Source: 

Link: https://it.wikipedia.org/wiki/Ferrovia_Cogne-Acque_Fredde

____

St. Sebastian Tended by Irene and her Maid, Hendrick Terbrugghen (1625)

 

{Click on image to enlarge}

Public Domain.

Source: 

Link: https://www.wikiart.org/en/hendrick-terbrugghen/st-sebastian-tended-by-irene-and-her-maid-1625

____

A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of #mRNA-Based Candidate #Pandemic #Influenza #Vaccines in Healthy Adults

 

Abstract

Background

Influenza A viruses pose a persistent pandemic threat. We report safety, reactogenicity, and immunogenicity findings for mRNA-1018 pandemic influenza vaccine candidates from a phase 1/2 study in healthy adults.

Methods

In Part A, participants were randomized to receive 1 of 4 mRNA-1018 candidates at 1 of 3 dose levels across 2 influenza A groups: (1) H5N8/H5-only or (2) H7N9/H7-only. H5N8 and H7N9 candidates were administered at 25, 50, or 100-µg and H5-only and H7-only at 12.5, 25, or 50-µg. Part B participants were randomized to receive 12.5, 25, or 50-µg H5-only-CG. Primary objectives were to evaluate the safety and reactogenicity of vaccine candidates. Secondary objectives included evaluation of humoral immunogenicity through day 205 by hemagglutination inhibition (HAI), neuraminidase inhibition, and microneutralization assays.

Results

Parts A and B comprised 1195 and 304 dosed participants, respectively. Overall, solicited local adverse reactions (ARs) within 7 days of vaccination occurred in 76.8% of participants across vaccine candidates and dose levels, most commonly injection-site pain. Solicited systemic ARs were reported in 62.8% of participants, most frequently fatigue and headache. Solicited ARs were predominantly grade 1–2 in severity, with few grade 3 and no grade 4 events. Post-vaccination immune responses, assessed absolutely, by HAI titers and dynamically, by seroconversion rates, tended to increase with vaccine dose. H5-based candidates induced stronger strain-specific HAI, but with comparable microneutralization titers, versus H7-based candidates.

Conclusions

Vaccine candidates were sufficiently well-tolerated and immunogenic. Further development of mRNA pandemic influenza vaccines is warranted for pandemic preparedness.

Source: 

Link: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciag278/8662346

____

#Coronavirus Disease Research #References (by AMEDEO, April 25 '26)

 

Ann Intern Med

1. FRITZ JM, Skolasky RL, Brennan G, Minick K, et al
   Effectiveness of Nonpharmacologic Treatments for Chronic Low Back Pain : A Sequential, Multiple-Assignment, Randomized Trial.
   Ann Intern Med. 2026 Apr 21. doi: 10.7326/ANNALS-25-04645.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. BAKER JV, Siegel L, Losso M, Vasudeva S, et al
   Ensitrelvir for the treatment of hospitalized adults with COVID-19: an international phase 3 randomized placebo-controlled trial.
   Clin Infect Dis. 2026 Apr 22:ciag272. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

3. ZHAO CY, Wang FS, Jiao YM
   SARS-CoV-2 infection disrupts the immune control status in a male HIV-1 elite controller.
   Int J Infect Dis. 2026 Apr 20:108713. doi: 10.1016/j.ijid.2026.108713.
   PubMed         Abstract available
   
   

   
   J Infect

4. BEHARIER O, Guedalia J, Sehtman-Shachar DR, Kerem L, et al
   Maternal SARS-CoV-2 Infection and Early Child Growth and Development: A Nationwide Cohort Study.
   J Infect. 2026 Apr 17:106749. doi: 10.1016/j.jinf.2026.106749.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. HO SY, Liu YC, Ho SY, Chen SH, et al
   Emergence of Echovirus 11 in Severe and Neonatal Enterovirus Infections: A 9-Year Retrospective Study in Taiwan Before and After the COVID-19 Pandemic.
   J Med Virol. 2026;98:e70929.
   PubMed         Abstract available
   
   
6. AVILA JP, Park P, Singh Y, Amaral PP, et al
   Multiorgan Molecular Landscape of Severe COVID-19 Revealed by Consensus Gene Signatures and RAB8B Targeting.
   J Med Virol. 2026;98:e70932.
   PubMed         Abstract available
   
   
7. KESKIN S, Pavel STI, Sak R, Bahadori F, et al
   Modified mRNA Encoding the Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Confers Robust Protection Against Lethal Challenge in Mice.
   J Med Virol. 2026;98:e70940.
   PubMed         Abstract available
   
   

   
   J Virol

8. SALISCH F, Muller-Ruttloff C
   Behind the membranous curtain-lipid dynamics and functions in coronaviral replication.
   J Virol. 2026 Apr 21:e0175325. doi: 10.1128/jvi.01753.
   PubMed         Abstract available
   
   
9. YANG M, Zhao Y, Guo W, Wang L, et al
   Development of a vaccine based on mRNA assembly of PEDV virus-like particle.
   J Virol. 2026 Apr 21:e0206025. doi: 10.1128/jvi.02060.
   PubMed         Abstract available
   
   
10. ZHANG K, Wang S, Kang X, Li F, et al
    Swine GBP1 restricts PDCoV replication via disrupting the replication and transcription complex formation.
    J Virol. 2026 Apr 21:e0020726. doi: 10.1128/jvi.00207.
    PubMed         Abstract available
    
    
11. ZHAO J, Tian J, Zhang L, Li Y, et al
    Coronavirus infectious bronchitis virus spike protein inhibits FUNDC1-mediated mitophagy to prevent nucleocapsid protein degradation.
    J Virol. 2026 Apr 20:e0180025. doi: 10.1128/jvi.01800.
    PubMed         Abstract available
    
    
12. MU S, Bai Y, Qiu R, Zhang F, et al
    Porcine hemagglutinating encephalomyelitis virus nucleocapsid protein targets RIG-I and IRF3 to evade IFN immunity.
    J Virol. 2026 Mar 30:e0211225. doi: 10.1128/jvi.02112.
    PubMed         Abstract available
    
    
13. ZHANG X, Li Y, Yuan J, Li Q, et al
    Metformin hydrochloride regulates glycolysis and inhibits PEDV replication by inhibition of PI3K-AKT signaling pathway.
    J Virol. 2026;100:e0014726.
    PubMed         Abstract available
    
    

    
    JAMA

14. LEFF B, Siu A, DeCherrie LV, Levine DM, et al
    Hospital at Home and Transforming US Health Care Delivery.
    JAMA. 2026 Apr 23. doi: 10.1001/jama.2026.4791.
    PubMed        
    
    
15. KUKOYI OM, Wang VS, Yao K, Cipriano CB, et al
    US State Actions Related to COVID-19 Vaccination Infrastructure and Access Amid Federal Shifts.
    JAMA. 2026 Apr 20:e265148. doi: 10.1001/jama.2026.5148.
    PubMed        
    
    

    
    Lancet Infect Dis

16. ZHANG L, Hoffmann M, Pohlmann S
    Does BA.3.2 epidemiology imply a change in SARS-CoV-2 evolution?
    Lancet Infect Dis. 2026 Apr 17:S1473-3099(26)00192.
    PubMed        
    
    

    
    N Engl J Med

17. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Nature

18. GALLO G, Di Nardo A, Lugano D, Roberts AJ, et al
    Heart-nosed bat alphacoronaviruses use human CEACAM6 to enter cells.
    Nature. 2026 Apr 22. doi: 10.1038/s41586-026-10394.
    PubMed         Abstract available
    
    
19. YAN H
    A bat coronavirus can enter human cells through a previously unknown gateway.
    Nature. 2026 Apr 22. doi: 10.1038/d41586-026-00908.
    PubMed        

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 25 '26)

 

Ann Intern Med

1. LIM SY, Lee J, Chang E, Kwon JS, et al
   Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-04883.
   PubMed         Abstract available
   
   
2. QASEEM A, Obley AJ, Yost J, Abraham GM, et al
   Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03766.
   PubMed         Abstract available
   
   
3. SOMMER I, Dobrescu A, Gadinger A, Sharifan A, et al
   Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03691.
   PubMed         Abstract available
   
   

   
   Biochemistry

4. MEDEIROS-SILVA J, Zhang Y, Hong M
   Phosphatidylinositol Interactions with the SARS-CoV-2 Envelope Protein Investigated by Lipid (13)C Labeling and Solid-State NMR.
   Biochemistry. 2026;65:1178-1191.
   PubMed         Abstract available
   
   

   
   J Infect

5. COX SN, Bennett JC, Casto AM, Hoffman KL, et al
   INFLUENZA HOUSEHOLD TRANSMISSION AND GENOMIC DIVERSITY IN THE UNITED STATES: A PROSPECTIVE COHORT STUDY, 2022-2024.
   J Infect. 2026 Apr 20:106748. doi: 10.1016/j.jinf.2026.106748.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG R, Jian X, Zhang Y, Sun Y, et al
   The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.
   J Virol. 2026 Apr 21:e0000626. doi: 10.1128/jvi.00006.
   PubMed         Abstract available
   
   
7. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   PubMed         Abstract available
   
   
8. KONG W, Zhang J, Song Y, Song J, et al
   Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.
   J Virol. 2026 Mar 30:e0027026. doi: 10.1128/jvi.00270.
   PubMed         Abstract available
   
   
9. XIU R, Wang Y, Cai W, Wang Q, et al
   Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.
   J Virol. 2026 Mar 30:e0007626. doi: 10.1128/jvi.00076.
   PubMed         Abstract available
   
   
10. BRENNAN JW, Wang G, Connor S, Wang X, et al
    A respiratory syncytial virus trailer sequence modulates viral replication and the generation and propagation kinetics of copy-back defective viral genomes.
    J Virol. 2026;100:e0018426.
    PubMed         Abstract available
    
    
11. ADAM A, Wu W, Jones MC, Hao H, et al
    Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through gammadelta T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells.
    J Virol. 2026 Mar 18:e0165825. doi: 10.1128/jvi.01658.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

12. BELL JM, Barbre K, Meng L, Lape-Newman B, et al
    Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2026;75:195-201.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Pediatrics

14. SEGEV N, Wilson E, Moehlman M, Corathers SD, et al
    Unmasking Adrenal Insufficiency: Adrenal Crisis Triggered by Influenza-Associated Encephalitis.
    Pediatrics. 2026 Apr 22:e2025072983. doi: 10.1542/peds.2025-072983.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

15. LI Y, Nielsen BF, Levin SA, Te Velthuis AJW, et al
    Spatio-temporal modelling of in vitro influenza A virus infection: The impact of defective interfering particles on the type I interferon response.
    PLoS Comput Biol. 2026;22:e1014198.
    PubMed         Abstract available
    
    
16. WHITE LA, Leon TM
    Forecastability of infectious disease time series: are some seasons and pathogens intrinsically more difficult to forecast?
    PLoS Comput Biol. 2026;22:e1014175.
    PubMed         Abstract available
    
    

    
    PLoS One

17. ORTEGA-MARTIN E, Alvarez-Galvez J
    Understanding quality-of-life patterns in long COVID: How Symptoms and socioeconomic conditions shape patient wellbeing.
    PLoS One. 2026;21:e0347743.
    PubMed         Abstract available
    
    
18. CHAVES SS, Castells VB, Mira-Iglesias A, Puig-Barbera J, et al
    Rhinovirus/enterovirus contribution to respiratory-associated hospitalizations in adults during respiratory seasons in Spain: A 6-year prospective study.
    PLoS One. 2026;21:e0347659.
    PubMed         Abstract available
    
    
19. LEE J, Bajiya VP, Jung E
    Vaccination scenario-based study on seasonal influenza in Republic of Korea.
    PLoS One. 2026;21:e0322686.
    PubMed         Abstract available
    
    
20. PIRZADA P, Wilde A, Doherty GH, Harris-Birtill D, et al
    Understanding older adults' perception, acceptance, and adoption of smart home technologies.
    PLoS One. 2026;21:e0345563.
    PubMed         Abstract available
    
    
21. FANG Z, Xu H, Mu Y
    Risk-taking responses to crash experience: Evidence from China.
    PLoS One. 2026;21:e0347543.
    PubMed         Abstract available
    
    
22. GARZA J, Sebastian R, Cover B, Sanchez A, et al
    Nicotine dependence among critically ill COVID-19 patients: A population-based cohort study.
    PLoS One. 2026;21:e0308776.
    PubMed         Abstract available
    
    
23. MCDONALD C, Grajales AG, Yahia NA, Fisman D, et al
    Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023.
    PLoS One. 2026;21:e0344690.
    PubMed         Abstract available
    
    
24. LOVATO N, Appleton SL, Reynolds AC, Gill TK, et al
    Relationships between pre-pandemic mental health, sociodemographic factors and health behaviours in older adults during the acute onset of COVID-19 in Australia: A descriptive analysis.
    PLoS One. 2026;21:e0346787.
    PubMed         Abstract available
    
    
25. AUDUREAU E, Jean C, Layese R, Neuraz A, et al
    Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.
    PLoS One. 2026;21:e0346679.
    PubMed         Abstract available
    
    
26. IPEKCI AM, Hodel EM, Filsinger M, Wegmuller S, et al
    Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey.
    PLoS One. 2026;21:e0346420.
    PubMed         Abstract available
    
    
27. YANG Z, Imouza A, Puelma Touzel M, Amadoro C, et al
    Regional and temporal patterns of partisan polarization during the COVID-19 pandemic in the United States and Canada.
    PLoS One. 2026;21:e0347327.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. SANDERS CG, Liu M, Fusco JA, Ohl EM, et al
    Efficient replication of influenza D virus in the human airway underscores zoonotic potential.
    Proc Natl Acad Sci U S A. 2026;123:e2530325123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. ROBERTSON AH, Wolf AS, Fossum E, Solum G, et al
    Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
    Vaccine. 2026;80:128511.
    PubMed         Abstract available
    
    
30. DLOUHY P, Petras M, Lesna IK, Macalik R, et al
    Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.
    Vaccine. 2026;80:128535.
    PubMed         Abstract available
    
    
31. VAN DE BURGWAL LHM, Pronker ES, Herz J
    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment.
    Vaccine. 2026;80:128525.
    PubMed         Abstract available
    
    
32. WU D, Liu K
    Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.
    Vaccine. 2026;80:128536.
    PubMed         Abstract available
    
    
33. MAEDA H, Saito N, Igarashi A, Ishida M, et al
    Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.
    Vaccine. 2026;80:128544.
    PubMed         Abstract available
    
    
34. MORO PL, Romanson B, Marquez P, Zhang B, et al
    Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.
    Vaccine. 2026;80:128547.
    PubMed         Abstract available
    
    
35. QUINTANAR-SOLARES M, Fleming JA, Musau W, Mulati F, et al
    RSV ready? Exploring feasibility and acceptability of RSV immunization options in low- and middle-income countries.
    Vaccine. 2026;80:128550.
    PubMed         Abstract available
    
    
36. KITANO T, Hashimoto E, Sado T, Yoshida S, et al
    Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: A retrospective cohort study.
    Vaccine. 2026;80:128566.
    PubMed         Abstract available
    
    
37. ZHANG L, Lin T, Wang M, Ma X, et al
    Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial.
    Vaccine. 2026;82:128588.
    PubMed         Abstract available
    
    
38. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.
    Vaccine. 2026;82:128582.
    PubMed         Abstract available
    
    
39. RICE E, Cheng AC, Britton PN, Carr J, et al
    Influenza epidemiology, treatment and prevention in Australian children: Trends from 6 years of PAEDS-FluCAN influenza surveillance (2019-2024).
    Vaccine. 2026;82:128592.
    PubMed         Abstract available

#Prion shedding is reduced by chronic wasting disease {#CWD} #vaccination

 

Abstract

Chronic wasting disease (CWD) is a strictly fatal and highly contagious prion disease of wild and farmed cervids currently expanding in North America. Prion diseases are caused by conversion of the cellular prion protein to its pathological isoform PrPSc. Vaccination is considered a promising strategy to contain CWD, even though prion diseases do not show classical immune responses. For CWD containment, it is important that vaccines reduce shedding of prions in excreta, a major contributor to transmission. Here, we tested the effect of vaccines on prion shedding in feces and urine by vaccinating and prion infecting knock-in mice that recapitulate CWD pathogenesis as found in cervids. Vaccination reduced or even prevented CWD shedding in feces and urine collected between 30–90% of incubation time to disease. This is the first report showing that prion shedding can be blocked in a prion disease. For CWD specifically it may reduce the environmental prion burden and break the disease transmission cycle.

Source: 

Link: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1014166

____

History of Mass Transportation: The Romanian Diesel Automotor Class 78-750

 

{Click on image to enlarge}

By Mirceacool at Romanian Wikipedia - Transferred from ro.wikipedia to Commons., Public Domain, https://commons.wikimedia.org/w/index.php?curid=8459557

Source: 

Link: https://en.wikipedia.org/wiki/Rolling_stock_of_the_Romanian_Railways

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, April 24 '26)

 

{Excerpt}

(...)

Time Period: April 12, 2026 - April 18, 2026

-- A(H5) Detection: 6 site(s) (1.3%)

-- No Detection: 444 site(s) (98.7%)

-- No samples: 103 site(s)

{Click on image to enlarge}

(...)

Source: 

Link: https://www.cdc.gov/wastewater/emerging-viruses/h5.html

____

#Chile - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 

Backyard non - poultry birds in the Maule Region.

Source: 

Link: https://wahis.woah.org/#/in-review/7490

____

#India - High pathogenicity avian #influenza #H5N1 viruses (Inf. with) (#poultry) - Immediate notification

 

A poultry farm in the Maharashtra State.

Source: 

Link: https://wahis.woah.org/#/in-review/7469

____

Detection of a #Merbecovirus with potential #ACE2 usage in #France

 

ABSTRACT

A novel Merbecovirus, designated Cam-2023, has been identified in Pipistrellus pipistrellus in France through non-invasive surveillance. Phylogenetic analysis demonstrates that Cam-2023 belongs to a Merbecovirus clade previously associated with ACE2 usage in closely related viruses detected in the Netherlands and Russia. While the receptor usage of Cam-2023 remains to be functionally validated, sequence similarities within the Spike protein, particularly the receptor-binding domain, suggest a putative association with a Merbecovirus clade previously associated with ACE2 usage. This discovery broadens the known host diversity of this lineage and extends its geographical range to Western Europe. Our findings highlight the importance of continuous surveillance in European bat populations to better characterize the distribution and zoonotic potential of such high-risk coronaviruses.

Source: 

Link: https://www.tandfonline.com/doi/full/10.1080/22221751.2026.2651469

____

Robustly Quantifying #Uncertainty in #International Avian #Influenza #H5N1 Infection #Fatality Ratios

 

Abstract

Knowing the mortality rates associated with infection by a pathogen is essential for effective preparedness and response. Here, harnessing the flexibility of a Bayesian approach, we produce an estimate of the Infection Fatality Ratio (IFR) for A(H5N1) conditional on explicit assumptions, and quantify the uncertainty thereof. We also apply the method to first-wave COVID-19 data up to March 2020, demonstrating the estimates that could be obtained were the model available then. Our analysis uses World Development Indicators (WDI) from the World Bank, the A(H5N1) WHO confirmed cases and deaths tracker by country (2003-2024), and COVID-19 cases and deaths data from John Hopkins University (January and February 2020). Since infectious disease dynamics are typically influenced by local socio-economic factors rather than political borders, individual countries are placed within clusters of countries sharing similar WDIs relevant to respiratory viral diseases, with clusters derived by performing Hierarchical Clustering. To estimate the IFR, we fit a Negative Binomial Bayesian Hierarchical Model for A(H5N1) and COVID-19 separately. We explicitly modelled key unobserved parameters with informative priors from expert opinion and literature. By modelling underreporting, our analysis suggests lower fatality (15.3%) compared to WHO's Case Fatality Ratio estimate (54%) on lab-confirmed cases. However, credible intervals are wide ([0.5%, 64.2%] 95% CrI). Therefore, good preparedness for a potential A(H5N1) pandemic implies adopting scenario planning under our central estimate, as well as for IFRs as high as 70%. Our approach also returns a COVID-19 IFR estimate of 2.8% with [2.5%, 3.1%] 95% CrI which is consistent with literature.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MKA is supported by the Schlumberger Foundation Faculty for the Future. TH is supported by the Wellcome Trust (Ref: 227438/Z/23/Z) and Medical Research Council (Ref: UKRI483). LG, MN, TF are employed by UKHSA. The research leading to these results received UK Government grant-in-aid funding to UKHSA. The views expressed in this publication are those of the authors and not necessarily those of UKHSA or Department for Health and Social Care. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Source: 

Link: https://www.medrxiv.org/content/10.64898/2026.04.22.26351373v1

____

An #NS1-F161L #Substitution Determines #Host-Driven #Virulence Enhancement of #H5N6 Avian #Influenza Virus in #Ducks

 

Abstract

H5 subtype avian influenza virus (AIV) can infect both chickens and ducks, leading to substantial economic losses. Nevertheless, certain strains cause silent infections in ducks. In this study, a goose-origin clade 2.3.4.4h H5N6 AIV was isolated, which caused high mortality in mixed-gender white leghorn chickens but no deaths in mixed-gender mallard ducks. After independent serial in vitro passage in duck embryo fibroblasts (DEFs) and in vivo passage in specific-pathogen-free (SPF) ducks, the DEF-passage 10 (P10) virus induced markedly higher mortality rates and viral loads in SPF ducks compared to the DEF-P1 virus and the original parental virus prior to passage. Similarly, the in vivo-passaged P3 and P4 viruses exhibited significantly higher mortality rates than the P1 virus in SPF ducks, with 100% mortality and markedly increased viral titers in the organs. A whole-genome SNP analysis identified seven high-frequency mutations in the M1, NA and NS1 proteins. The NS1-F161L substitution virus exhibited significantly increased mortality rates, viral loads in multiple tissues, and a robustly induced innate immune response in ducks. Furthermore, dynamic evolutionary variations in the NS1 protein among global H5 avian influenza viruses revealed that the NS1-F161L substitution became dominant in clade 2.3.4.4b viruses in 2021 and subsequent years. Collectively, our findings demonstrate that host-driven adaptation can rapidly increase the pathogenicity of H5N6 AIVs in ducks and identify NS1-F161L as a critical virulence marker. These results offer novel insights relevant to the molecular surveillance, virulence prediction, and risk assessment of circulating H5 AIVs in waterfowl.

Source: 

Link: https://www.mdpi.com/1999-4915/18/5/488

____